Skip to main content

Acrivon Therapeutics, Inc.

corporate_fare Company Profile

Acrivon Therapeutics, Inc.

ACRV·NASDAQ·Life Sciences·CIK 0001781174

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines. The company utilizes its proprietary Generative Phosphoproteomics Acrivon Predictive Precision Proteomics, or AP3, platform. This platform is designed to quantify compound-specific, drug-regulated pathway activity levels within intact cells in an unbiased manner, generating terabytes of proprietary data and providing rapid, actionable insights. The name "Acrivon" is derived from Greek for "accurate" or "precise," reflecting the platform's ability to match therapies with patients who will benefit. Acrivon's approach aims to overcome the limitations of genetics-based precision medicine, which currently addresses less than 10% of cancer patients with easily identifiable genetic mutations. The AP3 platform is engineered to measure compound-specific effects on the entire tumor cell protein, signaling network, and drug-induced resistance mechanisms in an unbiased, modality, and disease-agnostic way. This proteomics-based approach directly measures critical tumor-driving pathways, independent of underlying genetic alterations. Acrivon believes its method is applicable across drug development stages and therapeutic modalities, not limited to cancers driven by single gene driver mutations or susceptible to a synthetic lethal approach. The company believes its method is broadly applicable to the majority of cancers, particularly solid tumors, where genetics-based approaches have often been insufficient to identify patient responders. The AP3 platform is designed to enable the therapeutic addressing of a much larger percentage of tumors by using agents attuned to specific biochemical signaling pathways.

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for ACRV at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Acrivon Therapeutics Reports Strong Clinical Data for ACR-368 in Endometrial Cancer and Promising ACR-2316 Phase 1 Results
  • Acrivon Therapeutics Reports Strong Cash Position and Positive Clinical Data Across Multiple Programs

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$77.91M
Diluted EPS
-$2.02
Op. Cash Flow
-$63.66M
Free Cash Flow
-$65.33M
Operating Income
-$84.11M
Cash & Equivalents
$41.5M
Debt / Equity
0.00×
Shares Outstanding
31.65M sh
Source: 10-K · filed 2026-03-19 · accession 0001193125-26-115123
$1.16 +0.87% today
52-week range · as of 2026-11-20 $0.9709 – $3.56
Market cap
$49.35M
Volume
1.3M (4.9× avg)
3-mo avg 266.9K
Live data · 2026-11-21 15:36 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ACRV - Filings & News (Page 2)

ACRV
Jan 08, 2026, 9:00 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $2.79
Real-time Price: $1.16 info
Change: -$1.63 (-58%) info
Market Cap: $49.348M info
ACRV
Jan 08, 2026, 7:30 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $3.19
Real-time Price: $1.16 info
Change: -$2.03 (-64%) info
Market Cap: $49.348M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets